COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies

Br J Haematol. 2021 Apr;193(1):43-51. doi: 10.1111/bjh.17240. Epub 2021 Feb 4.

Authors

Eleonora Calabretta^{1

2}, Jose M Moraleda³, Massimo Iacobelli⁴, Ruben Jara⁵, Israel Vlodavsky⁶, Peter O'Gorman⁷, Antonio Pagliuca⁸, Clifton Mo⁹, Rebecca M Baron¹⁰, Alessio Aghemo^{11

2}, Robert Soiffer⁹, Jawed Fareed¹², Carmelo Carlo-Stella^{1

2}, Paul Richardson⁹

Affiliations

¹ Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.
² Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy.
³ Department of Hematology, Stem Cell Transplant and Cell Therapy Unit, Virgen de la Arrixaca University Hospital, IMIB-Arrixaca, University of Murcia, Murcia, Spain.
⁴ Techitra Srl, Milan, Italy.
⁵ Department of Critical Care Medicine, Virgen de la Arrixaca University Hospital, IMIB-Arrixaca, University of Murcia, Murcia, Spain.
⁶ The Rappaport Faculty of Medicine, Technion Integrated Cancer Center (TICC), Haifa, Israel.
⁷ Haematology Department, Mater Misericordiae University Hospital, Dublin, Ireland.
⁸ Department of Haematology, Kings College Hospital NHS Foundation Trust, London, UK.
⁹ Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
¹⁰ Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
¹¹ Division of Hepatology and Internal Medicine, Humanitas Clinical and Research Center - IRCCS, Milan, Italy.
¹² Loyola University Medical Center, Chicago, IL, USA.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anemia, Sickle Cell / complications
Anemia, Sickle Cell / physiopathology
Anticoagulants / therapeutic use
Apoptosis
Bone Marrow Transplantation / adverse effects
COVID-19 / complications*
COVID-19 / epidemiology
Endothelial Cells / pathology
Endothelial Cells / virology*
Endothelium, Vascular / virology*
Glucuronidase / antagonists & inhibitors
Graft vs Host Disease / etiology
Graft vs Host Disease / physiopathology
Heparin / therapeutic use
Hepatic Veno-Occlusive Disease / etiology
Hepatic Veno-Occlusive Disease / physiopathology
Humans
Idiopathic Interstitial Pneumonias / etiology
Idiopathic Interstitial Pneumonias / physiopathology
Interleukin-6 / physiology
Multiple Organ Failure / etiology
Multiple Organ Failure / physiopathology
Organ Specificity
Pandemics*
Polydeoxyribonucleotides / therapeutic use
SARS-CoV-2 / isolation & purification
SARS-CoV-2 / pathogenicity*
Stem Cell Transplantation / adverse effects
Thrombophilia / drug therapy
Thrombophilia / etiology
Thrombotic Microangiopathies / etiology
Thrombotic Microangiopathies / physiopathology
Vasculitis / drug therapy
Vasculitis / etiology*
Vasculitis / virology
Viral Tropism

Substances

Anticoagulants
IL6 protein, human
Interleukin-6
Polydeoxyribonucleotides
defibrotide
Heparin
heparanase
Glucuronidase

Grants and funding

#20575 to CC-S/AIRC